Lipid clinics worldwide: harmonization and guidance on how to optimally organize and fund

Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death worldwide, responsible for one in three deaths globally. Despite major advances in lipid testing, preventive therapies, and international treatment guidelines, implementation of optimal lipid management remains highly uneven across countries and healthcare systems. Many patients with familial hypercholesterolaemia (FH), elevated lipoprotein(a), severe hypertriglyceridaemia, statin intolerance, and other complex lipid disorders still lack access to specialized care, early diagnosis, and evidence-based treatment.